EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study

Mikkel Pejstrup Agger, Else Rubæk Danielsen, Marcus Schultz Carstensen, N Mai Nguyen, Maibritt Horning, Mark Alexander Henney, Christopher Boe Ravn Jensen, Anders Ohlhues Baandrup, Troels Wesenberg Kjær, Kristoffer Hougaard Madsen, Kamilla Miskowiak, Paul Michael Petersen und 1 weitere

Journal of Alzheimer's Disease · 21.03.2023 · 92 (2) · 653-665

DOI: 10.3233/jad-221238 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 21.03.2023. Verfasst von Mikkel Pejstrup Agger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Zealand University Hospital, Denmark. Hauptthemen laut MEDLINE: Alzheimer Disease, Phototherapy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent studies suggested induction of 40 Hz neural activity as a potential treatment for Alzheimer’s disease (AD). However, prolonged exposure to flickering light raises adherence and safety concerns, encouraging investigation of tolerable light stimulation protocols.

Objective

To investigate the safety, feasibility, and exploratory measures of efficacy.

Methods

This two-stage randomized placebo-controlled double-blinded clinical trial, recruited first cognitive healthy participants (n = 3/2 active/placebo), and subsequently patients with mild-to-moderate AD (n = 5/6, active/placebo). Participants were randomized 1:1 to receive either active intervention with 40 Hz Invisible Spectral Flicker (ISF) or placebo intervention with color and intensity matched non-flickering white light.

Results

Few and mild adverse events were observed. Adherence was above 86.1% of intended treatment days, with participants remaining in front of the device for >51.3 min (60 max) and directed gaze >34.9 min. Secondary outcomes of cognition indicate a tendency towards improvement in the active group compared to placebo (mean: –2.6/1.5, SD: 6.58/6.53, active/placebo) at week 6. Changes in hippocampal and ventricular volume also showed no tendency of improvement in the active group at week 6 compared to placebo. At week 12, a potential delayed effect of the intervention was seen on the volume of the hippocampus in the active group compared to placebo (mean: 0.34/–2.03, SD: 3.26/1.18, active/placebo), and the ventricular volume active group (mean: –0.36/2.50, SD: 1.89/2.05, active/placebo), compared to placebo.

Conclusion

Treatment with 40 Hz ISF offers no significant safety or adherence concerns. Potential impact on secondary outcomes must be tested in larger scale clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePhototherapyAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodFeasibility StudiesPilot ProjectsTreatment Outcome

Stichwörter der Autor:innen

40 HzAlzheimer’s diseasegamma entrainmentinvisible spectral flickerlight-based neurostimulation

Autor:innen und Institutionen

  • Department of Neurology, Zealand University Hospital, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Denmark.
  • Department of Radiology Zealand University Hospital, Denmark.
  • Department of Photonics Engineering, Technical University of Denmark, Denmark.
  • OptoCeutics ApS, Kgs. Lyngby, Denmark.
  • Department of Applied Mathematics and Computer Science, Technical University of Denmark, Denmark.

Zitieren

APA

Agger, M. P., Danielsen, E. R., Carstensen, M. S., Nguyen, N. M., Horning, M., Henney, M. A., Jensen, C. B. R., Baandrup, A. O., Kjær, T. W., Madsen, K. H., Miskowiak, K., Petersen, P. M., & Høgh, P. (2023). Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. Journal of Alzheimer's Disease, 92(2), 653-665. https://doi.org/10.3233/jad-221238

Vancouver

Agger MP, Danielsen ER, Carstensen MS, Nguyen NM, Horning M, Henney MA, et al. Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. Journal of Alzheimer's Disease. 2023;92(2):653-665. doi:10.3233/jad-221238

BibTeX
@article{Agger2023,
  author = {Agger, Mikkel Pejstrup and Danielsen, Else Rubæk and Carstensen, Marcus Schultz and Nguyen, N Mai and Horning, Maibritt and Henney, Mark Alexander and Jensen, Christopher Boe Ravn and Baandrup, Anders Ohlhues and Kjær, Troels Wesenberg and Madsen, Kristoffer Hougaard and Miskowiak, Kamilla and Petersen, Paul Michael and Høgh, Peter},
  title = {Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study},
  journal = {Journal of Alzheimer's Disease},
  year = {2023},
  volume = {92},
  number = {2},
  pages = {653--665},
  doi = {10.3233/jad-221238}
}
Kostenlos starten →